Zynex (NASDAQ:ZYXI – Get Rating) had its target price lowered by HC Wainwright from $21.00 to $20.00 in a report published on Tuesday, The Fly reports.
Separately, Piper Sandler raised shares of Zynex from a neutral rating to an overweight rating and raised their price objective for the stock from $10.00 to $18.00 in a research note on Friday, January 6th.
Zynex Stock Up 1.6 %
Shares of NASDAQ:ZYXI opened at $11.12 on Tuesday. The company has a current ratio of 3.41, a quick ratio of 2.68 and a debt-to-equity ratio of 0.10. Zynex has a 12 month low of $5.03 and a 12 month high of $17.25. The company has a 50-day moving average price of $13.63 and a 200 day moving average price of $12.15. The company has a market cap of $416.48 million, a price-to-earnings ratio of 25.27 and a beta of 0.65.
Institutional Trading of Zynex
Several institutional investors have recently added to or reduced their stakes in ZYXI. JPMorgan Chase & Co. lifted its stake in Zynex by 183.5% in the second quarter. JPMorgan Chase & Co. now owns 626,319 shares of the company’s stock worth $4,998,000 after purchasing an additional 405,396 shares during the last quarter. BlackRock Inc. increased its position in shares of Zynex by 12.7% during the first quarter. BlackRock Inc. now owns 3,419,912 shares of the company’s stock worth $21,307,000 after acquiring an additional 384,548 shares during the period. Federated Hermes Inc. increased its position in shares of Zynex by 1,148.0% during the first quarter. Federated Hermes Inc. now owns 222,563 shares of the company’s stock worth $1,387,000 after acquiring an additional 204,729 shares during the period. Rice Hall James & Associates LLC increased its position in shares of Zynex by 206.3% during the third quarter. Rice Hall James & Associates LLC now owns 203,921 shares of the company’s stock worth $1,850,000 after acquiring an additional 137,353 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Zynex by 147.0% during the first quarter. Renaissance Technologies LLC now owns 192,035 shares of the company’s stock worth $1,196,000 after acquiring an additional 114,277 shares during the period. Institutional investors own 28.64% of the company’s stock.
Zynex, Inc engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.
- Get a free copy of the StockNews.com research report on Zynex (ZYXI)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.